title: [YB-1 as a potential target in cancer therapy].
abstract: The 42-kDa multifunctional cellular protein Y-box protein 1 (YB-1) is expressed in various cancers. It is localized in the cytoplasm as well as in the nucleus. In particular, YB-1 is localized in the nuclear compartment following cellular stress, such as radiation, drug treatment, hyperthermia, or viral infection. Within the nucleus, YB-1 can act as a transcription factor, and it is involved in the regulation of important cancer-associated genes. For example, YB-1 triggers the expression of Her-2 and estrogen receptor alpha (ERalpha) in breast cancer. Thus, nuclear YB-1 appears to be a potential target for the inhibition of Her-2- and ERalpha-dependent proliferation signals, particularly with regard to resistance to Her-2-targeting drugs such as trastuzumab. In some cancers, YB-1 may be involved in regulating MDR1/P-glycoprotein, mediating classical multidrug resistance (MDR). Furthermore, YB-1 is involved in the replication of adenovirus type 5, a commonly used vector in gene therapy. Thus, YB-1 can trigger an "oncolytic" effect in YB-1 nuclear positive cancer cells treated with adenoviruses. Besides its impact as a prognostic factor, in the future the diagnostics of cellular YB-1 status may provide the basis for a virotherapy or a gene therapy incorporating adenoviruses.
authors.affiliation: Institut für Pathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin. hermann.lage@charite.de
authors.forename: H
authors.initials: H
authors.lastname: Lage
authors.forename: P
authors.initials: P
authors.lastname: Surowiak
authors.forename: P S
authors.initials: PS
authors.lastname: Holm
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics / Q000628:therapy; D002455:Cell Division / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D047628:Estrogen Receptor alpha / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D009687:Nuclear Proteins / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D051840:Y-Box-Binding Protein 1
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004268:DNA-Binding Proteins; D047628:Estrogen Receptor alpha; D009687:Nuclear Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D051840:Y-Box-Binding Protein 1; C513055:ABCB1 protein, human; C070856:YBX1 protein, human; C508053:ERBB2 protein, human
references.citation: Cancer Res. 2005 May 15;65(10):4078-87
references.pmid: 15899797
references.citation: Cancer Res. 2004 Jan 1;64(1):322-8
references.pmid: 14729641
references.citation: Cancer Lett. 2003 Feb 20;190(2):191-7
references.pmid: 12565174
references.citation: J Biol Chem. 2002 Mar 22;277(12):10427-34
references.pmid: 11788582
references.citation: Transl Oncogenomics. 2007 May 11;2:49-65
references.pmid: 23641145
references.citation: Cancer Sci. 2007 Jul;98(7):1020-6
references.pmid: 17459055
references.citation: J Biol Chem. 2001 Jul 27;276(30):28562-9
references.pmid: 11369762
references.citation: Clin Cancer Res. 2001 Oct;7(10):3151-5
references.pmid: 11595709
references.citation: Prostate. 2004 May 15;59(3):337-49
references.pmid: 15042610
references.citation: Cancer Res. 2008 Mar 1;68(5):1504-12
references.pmid: 18316615
references.citation: Bioessays. 2003 Jul;25(7):691-8
references.pmid: 12815724
references.citation: Cancer Res. 2006 Jul 15;66(14):7195-202
references.pmid: 16849566
references.citation: Int J Cancer. 2002 Jan 20;97(3):278-82
references.pmid: 11774277
references.citation: Radiother Oncol. 2008 Mar;86(3):419-27
references.pmid: 17967494
references.citation: J Pathol. 2003 Feb;199(2):251-8
references.pmid: 12533839
references.citation: Clin Cancer Res. 1998 Sep;4(9):2273-7
references.pmid: 9748149
references.citation: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8837-44
references.pmid: 16361573
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1196-208
references.pmid: 17401009
references.citation: Biochem Biophys Res Commun. 2007 May 25;357(1):295-301
references.pmid: 17418094
references.citation: Cancer Res. 2006 May 1;66(9):4872-9
references.pmid: 16651443
references.citation: Nat Rev Cancer. 2005 Dec;5(12):921-9
references.pmid: 16341083
references.citation: J Biol Chem. 2003 Jul 25;278(30):27988-96
references.pmid: 12695516
references.citation: Future Oncol. 2005 Feb;1(1):103-13
references.pmid: 16555980
references.citation: Int J Oncol. 2007 Aug;31(2):419-30
references.pmid: 17611700
references.citation: Proc Natl Acad Sci U S A. 1988 Oct;85(19):7322-6
references.pmid: 3174636
references.citation: Genes Dev. 1993 Sep;7(9):1725-36
references.pmid: 8370522
references.citation: Nat Med. 1997 Apr;3(4):447-50
references.pmid: 9095180
references.citation: Int J Cancer. 1999 Dec 10;83(6):732-7
references.pmid: 10597187
references.citation: Cancer. 1999 Jun 1;85(11):2450-4
references.pmid: 10357417